7 Best NASDAQ Stocks Under $5

3. Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Stock Price as of September 27: $1.68

Number of Hedge Fund Holders: 26

One of the best NASDAQ stocks under $5 on our list, Esperion Therapeutics, Inc. (NASDAQ:ESPR) is dedicated to developing innovative medications aimed at improving the health outcomes of patients facing cardiovascular and cardiometabolic diseases.

The company has successfully launched several products, including NEXLETOL and NEXLIZET. These once-daily oral medications target primary hyperlipidemia in adults with conditions like heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease.

They provide an effective alternative for patients who need further lowering of LDL cholesterol levels. Additional products in the lineup include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that reduces LDL cholesterol by impacting cholesterol biosynthesis, and NUSTENDI, another combination medication aimed at managing elevated LDL-C.

At a stake value of $98.59 million, 26 hedge funds tracked by Insider Monkey held positions in Esperion Therapeutics (NASDAQ:ESPR) in the second quarter. As of Q2, Millennium Management is the top shareholder in the company and has a position worth $14.46 million.

Esperion Therapeutics (NASDAQ:ESPR) recent financial results indicate a significant upward trend in revenue, which reflects the company’s expanding market presence and product acceptance.

For the second quarter, it reported total revenue of $73.8 million, an impressive increase of 186% compared to $25.8 million during the same period in 2023. For the first half of the year, revenues soared to $211.6 million, a remarkable 322% rise from the previous year’s $50.1 million.

The growth is largely attributed to collaboration revenues, which surged by approximately 727% and 1138% for the three and six months ended June 30, 2024, respectively. The increase was driven by revenue from a Settlement Agreement with DSE, along with heightened product sales to international partners.

The company maintains its operational expense guidance for 2024 and projects expenses between $225 million and $245 million, which includes $20 million in non-cash stock compensation. The disciplined financial management, combined with rapidly growing revenues, positions the company for sustained growth.